For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Tafamidis meglumine represents a true advancement . These novel therapies protect the transthyretin protein, slowing its damaging build-up and lessening the impact of the illness. Patients are now seeing benefits in their h